DV Biomed (Taiwan) Today
| 6539 Stock | TWD 66.10 2.50 3.93% |
PerformanceWeak
| Odds Of DistressLow
|
DV Biomed is selling for under 66.10 as of the 19th of March 2025; that is 3.93% up since the beginning of the trading day. The stock's lowest day price was 64.0. DV Biomed has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company was founded in 2011 and is based in Taipei, Taiwan. UnicoCell operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.. The company has 59.26 M outstanding shares. More on DV Biomed Co
Moving against 6539 Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
6539 Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. DV Biomed's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding DV Biomed or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Liqi Zhang |
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
DV Biomed Co (6539) is traded on Taiwan OTC Exchange in Taiwan and employs 316 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.03 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DV Biomed's market, we take the total number of its shares issued and multiply it by DV Biomed's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. DV Biomed operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 59.26 M outstanding shares.
DV Biomed Co has accumulated about 538.29 M in cash with 463.36 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.14.
Check DV Biomed Probability Of Bankruptcy
DV Biomed Risk Profiles
Although DV Biomed's alpha and beta are two of the key measurements used to evaluate DV Biomed's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.25 | |||
| Standard Deviation | 2.18 | |||
| Variance | 4.76 | |||
| Risk Adjusted Performance | (0.01) |
6539 Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in DV Biomed without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
DV Biomed Corporate Management
Elected by the shareholders, the DV Biomed's board of directors comprises two types of representatives: DV Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 6539. The board's role is to monitor DV Biomed's management team and ensure that shareholders' interests are well served. DV Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DV Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Qunzhi Chen | Independent Director | Profile | |
| Peter Hou | Independent Director | Profile | |
| RongChun Lin | Independent Director | Profile | |
| Senxiong Zhang | Independent Director | Profile | |
| Qingjun Huang | Deputy General Manager-Administration Division | Profile |
Additional Tools for 6539 Stock Analysis
When running DV Biomed's price analysis, check to measure DV Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DV Biomed is operating at the current time. Most of DV Biomed's value examination focuses on studying past and present price action to predict the probability of DV Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DV Biomed's price. Additionally, you may evaluate how the addition of DV Biomed to your portfolios can decrease your overall portfolio volatility.